Shares of Merus Labs International Inc. (NASDAQ:MSLI) (TSE:MSL) have earned a consensus recommendation of “Hold” from the twelve brokerages that are covering the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $2.53.

A number of equities research analysts recently commented on the company. Citigroup Inc. reiterated a “neutral” rating on shares of Merus Labs International in a research report on Tuesday, November 8th. Zacks Investment Research upgraded Merus Labs International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 19th. Paradigm Capital reiterated a “hold” rating and issued a $1.60 target price (down previously from $1.75) on shares of Merus Labs International in a research report on Wednesday, October 5th. Finally, Canaccord Genuity reiterated a “buy” rating on shares of Merus Labs International in a research report on Friday, August 12th.

Several hedge funds and other institutional investors have recently made changes to their positions in MSLI. TD Asset Management Inc. raised its position in shares of Merus Labs International by 8.1% in the second quarter. TD Asset Management Inc. now owns 182,092 shares of the company’s stock worth $231,000 after buying an additional 13,681 shares during the period. Bank of Montreal Can acquired a new position in shares of Merus Labs International during the second quarter worth about $103,000. Morgan Stanley raised its position in shares of Merus Labs International by 30.7% in the third quarter. Morgan Stanley now owns 351,900 shares of the company’s stock worth $362,000 after buying an additional 82,625 shares during the period. Vertex One Asset Management Inc. raised its position in shares of Merus Labs International by 57.4% in the second quarter. Vertex One Asset Management Inc. now owns 314,700 shares of the company’s stock worth $400,000 after buying an additional 114,700 shares during the period. Finally, Guardian Capital LP raised its position in shares of Merus Labs International by 21.1% in the second quarter. Guardian Capital LP now owns 1,208,400 shares of the company’s stock worth $1,533,000 after buying an additional 210,500 shares during the period. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Shares of Merus Labs International (NASDAQ:MSLI) opened at 0.88 on Thursday. Merus Labs International has a 52-week low of $0.85 and a 52-week high of $1.90. The company’s market cap is $102.96 million. The stock’s 50 day moving average is $0.95 and its 200 day moving average is $1.14.

Merus Labs International Company Profile

Merus Labs International Inc (Merus) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives.

5 Day Chart for NASDAQ:MSLI

Receive News & Stock Ratings for Merus Labs International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc. and related stocks with our FREE daily email newsletter.